HRAS Antibody

Basic Research Questions

• What is HRAS and why is it an important target for antibody-based detection in research?

  HRAS (Harvey rat sarcoma viral oncogene homolog) is a 21 kDa protein belonging to the RAS family of small GTPases. It functions as a molecular signal transduction switch on the inner surface of the plasma membrane and endomembranes . HRAS plays critical roles in multiple cellular processes including differentiation, proliferation, adhesion, migration, and apoptosis . As a proto-oncogene, mutations in HRAS are associated with various cancers and Costello syndrome, a rare developmental disorder characterized by facial, cardiovascular, and musculoskeletal abnormalities .

  HRAS antibodies enable researchers to:

  • Track protein expression levels across different cell types and tissues

  • Monitor subcellular localization patterns

  • Study signal transduction networks

  • Investigate activation status (GTP vs. GDP-bound forms)

  • Examine molecular alterations in disease states

• What applications are HRAS antibodies validated for and what are the recommended dilutions?

  HRAS antibodies are validated for multiple applications with specific dilution requirements:

  Application	Recommended Dilution	Positive Detection Examples
  Western Blot (WB)	1:500-1:2000	HEK-293, SH-SY5Y, PC-3, C6, NIH/3T3 cells
  Immunoprecipitation (IP)	0.5-4.0 μg per 1.0-3.0 mg total protein	Mouse brain tissue, HEK-293 cells
  Immunohistochemistry (IHC)	1:50-1:500	Human colon cancer tissue
  Immunofluorescence (IF/ICC)	1:200-1:800	MCF-7, HepG2 cells
  Flow Cytometry (FC)	0.40 μg per 10^6 cells	HeLa cells

  When designing experiments, these dilutions should be optimized for your specific sample types and detection systems .

• How can I validate the specificity of an HRAS antibody?

  Validating HRAS antibody specificity requires multiple complementary approaches:

  • Knockout/knockdown controls: Compare signal in wild-type versus HRAS knockout/knockdown cells. For example, studies have shown that HRAS antibody Y132 produces a 21 kDa band in wild-type HEK-293 cells that is significantly reduced in HRAS siRNA knockdown cells (33% reduction with 6 μL siRNA and 49% reduction with 8 μL siRNA) .

  • Cross-reactivity testing: Confirm the antibody doesn't recognize related proteins like KRAS and NRAS. For instance, antibody CL488-18295 is specifically noted to recognize HRAS but not NRAS or KRAS .

  • Peptide competition: Pre-incubate the antibody with immunizing peptide prior to sample application. Specific signals should be blocked.

  • Molecular weight verification: HRAS has a calculated and observed molecular weight of 21 kDa .

  • Multiple antibodies: Use different antibodies targeting distinct HRAS epitopes and compare detection patterns .

• What buffer systems and antigen retrieval methods are recommended for HRAS antibody applications?

  The optimal buffer systems vary by application:

  • Western blot: Standard PBS-based buffers with 0.02% sodium azide and 50% glycerol at pH 7.3 for antibody storage .

  • Immunohistochemistry: For formalin-fixed paraffin-embedded tissues, TE buffer at pH 9.0 is the primary recommended antigen retrieval method. Alternatively, citrate buffer at pH 6.0 can be used .

  • Immunofluorescence: PBS with 50% glycerol, 0.05% Proclin300, and 0.5% BSA at pH 7.3 for fluorescently conjugated antibodies .

  • Storage conditions: Most HRAS antibodies should be stored at -20°C, with fluorescently labeled antibodies requiring protection from light exposure . They typically remain stable for one year after shipment when stored properly.

• What controls should I include when using HRAS antibodies?

  Robust experimental design requires multiple controls:

  • Positive controls: Include samples known to express HRAS, such as HEK-293, HeLa, NIH/3T3, MCF-7 cells, or mouse kidney tissue .

  • Negative controls:

    • Primary antibody omission control

    • Isotype control (matching the host species and isotype, typically Rabbit IgG for polyclonal antibodies)

    • HRAS knockout or siRNA knockdown samples

  • Loading controls: For quantitative analysis in Western blots, include housekeeping proteins like GAPDH .

  • Treatment controls: For studies involving HRAS modulation, include farnesyltransferase inhibitor (FTI) treatment, which affects HRAS membrane localization and can alter detection patterns .

Advanced Research Questions

• How can I distinguish between nuclear and cytoplasmic HRAS populations?

  HRAS localizes to both cytoplasmic and nuclear compartments with distinct patterns through the cell cycle . To effectively study these populations:

  • Cell fractionation: Perform careful subcellular fractionation with appropriate markers to confirm separation (e.g., tubulin for cytoplasm). Studies have confirmed that the 21 kDa HRAS protein is detectable in both nuclear and cytoplasmic fractions of various cell types including NIH 3T3, L cells, and primary fibroblasts .

  • Immunofluorescence optimization: For nuclear HRAS detection, use higher antibody concentrations (1:50-1:200 range) and enhanced permeabilization protocols. Signal intensity for nuclear HRAS becomes stronger during S phase .

  • Cell synchronization: Synchronize cells using serum starvation/stimulation to observe cell-cycle dependent localization patterns. Nuclear HRAS levels increase following serum addition to serum-starved cells, correlating with cyclin D1 expression .

  • Farnesyltransferase inhibition: Treatment with farnesyltransferase inhibitor (FTI) causes measurable decreases in nuclear HRAS. At 10 μM FTI, nuclear HRAS decreased by 83%, and at 50 μM FTI, it decreased by 93%, while cytoplasmic HRAS increased by 32-48% .

• How do HRAS mutations affect antibody detection, and what special considerations apply?

  HRAS mutations can influence antibody detection through multiple mechanisms:

  • Conformational changes: Mutations, particularly in the GTP-binding domain, can alter protein folding, potentially masking epitopes recognized by certain antibodies.

  • Subcellular localization: Oncogenic mutations can alter HRAS trafficking between membrane compartments. For instance, the H-Ras hypervariable region (HVR) is crucial for proper activation, as demonstrated by chimeric protein studies showing that the HVR (amino acids 166-189) determines HRAS activation status .

  • Protein stability: Some mutations enhance protein stability, potentially leading to stronger signals in antibody-based assays.

  When studying mutant HRAS:

  • Use multiple antibodies targeting different epitopes

  • Include wild-type controls alongside mutant samples

  • Consider paired antibodies that can distinguish active (GTP-bound) vs. inactive (GDP-bound) conformations

  • For oncogenic mutations, complement antibody detection with functional assays

• How can I use HRAS antibodies to study signal transduction networks at specific subcellular localizations?

  HRAS functions at distinct subcellular compartments with different signaling outputs. To study site-specific signaling:

  • Site-specific activation: Use tools like CDC25 constructs targeted to specific subcellular locations (e.g., ER, Golgi, plasma membrane) to selectively activate endogenous HRAS pools. Research has shown that different site-specific CDC25 constructs activate endogenous HRAS to varying degrees, with ER (M1) and DM (CD8) locations showing highest levels of Ras activation in HeLa cells .

  • Co-immunoprecipitation: Use HRAS antibodies for IP (0.5-4.0 μg per 1.0-3.0 mg total protein) followed by detection of downstream effectors to identify compartment-specific interactors .

  • Proximity labeling: Combine HRAS antibodies with proximity ligation assays to visualize interactions with effectors at specific locations.

  • Fractionation approaches: Isolate different membrane compartments (e.g., plasma membrane, ER, Golgi) before immunoblotting with HRAS antibodies to quantify distribution and activation status.

  • Live-cell imaging: For dynamic studies, use fluorescently-conjugated antibodies like CL488-18295 (excitation/emission: 493nm/522nm) for live cell applications .

• What are the key differences between antibodies for HRAS, KRAS, and NRAS detection?

  Despite high sequence homology between RAS isoforms, several key differences influence antibody selection:

  • Epitope selection: Isoform-specific antibodies typically target the hypervariable region (HVR) at the C-terminus, which differs significantly between isoforms. For example, the H-Ras-03 mouse monoclonal antibody targets a synthetic peptide corresponding to amino acids DIHQYREQIKRVKDSDDC of human H-Ras .

  • Validation strategies: Rigorous validation for isoform-specific antibodies requires:

    • Testing in cells with knockout/knockdown of specific RAS isoforms

    • Testing against overexpressed individual RAS isoforms

    • Cross-validation with multiple antibodies

  • Applications sensitivity: Immunoblotting typically offers better isoform discrimination than immunohistochemistry or immunofluorescence. For example, the CL488-18295 antibody is specifically noted to recognize HRAS but not NRAS or KRAS .

  • Post-translational modifications: HRAS undergoes a continuous cycle of de- and re-palmitoylation that regulates its rapid exchange between the plasma membrane and the Golgi apparatus , which may influence epitope accessibility differently than other RAS isoforms.

• How do I optimize detection of endogenous versus overexpressed HRAS?

  Detecting endogenous HRAS presents different challenges than overexpressed systems:

  Parameter	Endogenous HRAS	Overexpressed HRAS
  Antibody concentration	Higher (1:50-1:500)	Lower (1:1000-1:2000)
  Exposure time	Longer	Shorter
  Blocking	5% BSA often preferred	Standard blocking sufficient
  Controls	Knockdown/knockout essential	Vector-only controls
  Signal amplification	Often necessary	Generally not required

  For endogenous detection:

  • Use cell lines with confirmed HRAS expression (HEK-293, SH-SY5Y, PC-3, C6, NIH/3T3)

  • Increase protein loading (50-100 μg total protein)

  • Consider enhanced chemiluminescence systems

  • Use signal enhancement systems for immunofluorescence

  For overexpressed systems:

  • Titrate antibody to avoid saturation

  • Include wild-type HRAS as control for mutant studies

  • Consider epitope tags if antibody performance is suboptimal

• What methodological considerations apply when using HRAS antibodies for quantitative analyses?

  For accurate quantitation of HRAS using antibody-based methods:

  • Standard curves: Include recombinant HRAS protein standards at known concentrations.

  • Normalization: Use validated housekeeping proteins or total protein staining methods appropriate for your sample type. GAPDH is commonly used in Western blot applications .

  • Dynamic range: Determine the linear range of detection for your specific antibody and detection system through dilution series experiments.

  • Replication: Include biological triplicates and technical duplicates at minimum.

  • Statistical analysis: Apply appropriate statistical tests based on data distribution.

  • Controls for activation state: If measuring active HRAS, include positive controls (e.g., EGF stimulation) and negative controls (e.g., serum starvation).

  • Batch effects: Process all comparative samples simultaneously and include inter-experimental calibrators for multi-batch studies.

  • Quantification software: Use appropriate software that can distinguish specific signals from background, particularly important for immunofluorescence quantification.

• How can I use HRAS antibodies to study cell cycle-dependent expression and localization?

  HRAS shows dynamic expression patterns and subcellular distribution changes throughout the cell cycle :

  • Cell synchronization protocols:

    • Serum starvation (0.5% serum for 24-48 hours) followed by serum stimulation

    • Thymidine double block for S-phase synchronization

    • Nocodazole treatment for M-phase arrest

  • Time course experiments: Following synchronization, collect samples at regular intervals (e.g., every 2-4 hours) for 24-48 hours to capture complete cell cycle progression.

  • Co-staining approaches: Combine HRAS antibody staining with cell cycle markers:

    • Cyclin D1 for G1 phase

    • EdU incorporation for S phase

    • Phospho-Histone H3 for M phase

  • Quantitative imaging: Use high-content imaging systems to quantify nuclear/cytoplasmic HRAS ratios across cell populations.

  Research has demonstrated that nuclear HRAS signals become notably stronger at time points where the largest percentage of cells are in S phase, and this cycling occurs in both nontransformed and transformed cells .